

Prejbisz A, Dobrowolski P, Kosiński P, et al. Management of hypertension in pregnancy: prevention, diagnosis, treatment and long-term prognosis. A position statement of the Polish Society of Hypertension, Polish Cardiac Society and Polish Society of Gynecologists and Obstetricians. *Kardiol Pol.* 2019; 77: 757-806. doi:10.33963/KP.14904

REFERENCES

- 1 Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. *Pregnancy Hypertens.* 2018; 13: 291-310.
- 2 Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J.* 2018; 39: 3165-3241.
- 3 Tykarski A, Filipak KJ, Januszewicz A et al, et al. Zasady postępowania w nadciśnieniu tętniczym 2019. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego [2019 Guidelines for the Management of Hypertension. Recommendations of the Polish Society of Hypertension]. *Nadciśnienie Tętnicze w Praktyce.* 2019; 5: 1-86.
- 4 Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J.* 2018; 39: 3021-3104.
- 5 Zhou M, Daubresse M, Stafford RS, et al. National trends in the ambulatory treatment of hypertension in the United States, 1997-2012. *PLoS One.* 2015; 10: e0119292.
- 6 American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol.* 2013; 122: 1122-1131.
- 7 Lowe SA, Bowyer L, Lust K, et al. The SOMANZ Guidelines for the management of hypertensive disorders of pregnancy 2014. *Aust N Z J Obstet Gynaecol.* 2015; 55: 11-16.
- 8 Magee LA, Pels A, Helewa M, et al. Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. *J Obstet Gynaecol Can.* 2014; 36: 416-441.
- 9 Mounier-Vehier C, Amar J, Boivin JM, et al. Hypertension and pregnancy: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology. *Fundamental & Clinical Pharmacology.* 2016; 31: 83-103.
- 10 Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. *Lancet Glob Health.* 2014; 2: e323-e333.
- 11 Gillon TER, Pels A, von Dadelszen P, et al. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. *PLoS One.* 2014; 9: e113715.
- 12 Bramham K, Parnell B, Nelson-Piercy C, et al. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. *BMJ.* 2014; 348: g2301.
- 13 Chahine KM, Sibai BM. Chronic hypertension in pregnancy: new concepts for classification and management. *Am J Perinatol.* 2019; 36: 161-168.
- 14 ACOG Practice Bulletin No. 203 Summary: chronic hypertension in pregnancy. *Obstet Gynecol.* 2019; 133: 215-219.
- 15 Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. *Circulation.* 2001; 104: 515-521.
- 16 Brown MA. Is there a role for ambulatory blood pressure monitoring in pregnancy? *Clin Exp Pharmacol Physiol.* 2014; 41: 16-21.
- 17 Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? *Am J Hypertens.* 2001; 14: 1263-1269.
- 18 Malha L, August P. Secondary hypertension in pregnancy. *Curr Hypertens Rep.* 2015; 17: 53.
- 19 Bello NA, Miller E, Cleary K, et al. Out of office blood pressure measurement in pregnancy and the postpartum period. *Curr Hypertens Rep.* 2018; 20: 101.
- 20 Brown MA, Roberts L, Davis G, et al. Can we use the Omron T9P automated blood pressure monitor in pregnancy? *Hypertens Pregnancy.* 2011; 30: 188-193.
- 21 Prejbisz A, Kabat M, Januszewicz A. Pomiary ciśnienia tętniczego poza gabinetem lekarskim. Metody, interpretacja i zastosowanie w praktyce [Out-of-office blood pressure measurements. Methods, interpretation and clinical practice]. *Medycyna Praktyczna, Kraków* 2017.
- 22 Feldman D. Blood pressure monitoring during pregnancy. *Blood Pressure Monitoring.* 2001; 6: 1-7.
- 23 Phelan LK, Brown MA, Davis GK, et al. A prospective study of the impact of automated dipstick urinalysis on the diagnosis of preeclampsia. *Hypertens Pregnancy.* 2004; 23: 135-142.
- 24 Cade TJ, Gilbert SA, Polyakov A, et al. The accuracy of spot urinary protein-to-creatinine ratio in confirming proteinuria in pre-eclampsia. *Aust N Z J Obstet Gynaecol.* 2012; 52: 179-182.
- 25 Waugh J, Hooper R, Lamb E, et al. Spot protein-creatinine ratio and spot albumin-creatinine ratio in the assessment of pre-eclampsia: a diagnostic accuracy study with decision-analytic model-based economic evaluation and acceptability analysis. *Health Technol Assess.* 2017; 21: 1-90.
- 26 Redman CWG. Hypertension in pregnancy: the NICE guidelines. *Heart.* 2011; 97: 1967-1969.
- 27 Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2015; 28: 1-39.e14.
- 28 Cornette J, Ruys TPE, Roos-Hesselink JW, et al. Hemodynamic adaptation to pregnancy in women with structural heart disease. *Int J Cardiol.* 2013; 168: 825-831.
- 29 Committee on Obstetric P. Committee Opinion No. 723: guidelines for diagnostic imaging during pregnancy and lactation. *Obstet Gynecol.* 2017; 130: e210-e216.
- 30 Abramowicz J. Benefits and risks of ultrasound in pregnancy. *Semin Perinatol.* 2013; 37: 295-300.
- 31 American Institute of Ultrasound in Medicine. Statement on the Safe Use of Doppler Ultrasound During 11-14 week scans (or earlier in pregnancy). AIUM 2011, revised 2016. www.aium.org/officialStatements.17. Accessed July 31, 2018.
- 32 Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document on MR safe practices: 2013. *J Magn Reson Imaging.* 2013; 37: 501-530.
- 33 Tirada N, Dreizin D, Khatri NJ, et al. Imaging pregnant and lactating patients. *Radiographics.* 2015; 35: 1751-1765.
- 34 Albert TSE, Akahane M, Parienty I, et al. An international multicenter comparison of time-SLIP unenhanced MR angiography and contrast-enhanced CT angiography for assessing renal artery stenosis: the renal artery contrast-free trial. *AJR Am J Roentgenol.* 2015; 204: 182-188.
- 35 Bekiesińska-Figatowska M, Romaniuk-Doroszewska A, Brągoszewska H, et al. Diagnostic imaging of pregnant women. The role of magnetic resonance imaging. *Pol J Radiol.* 2017; 82: 220-226.
- 36 Sjösten N, Nabi H, Westerlund H, et al. Effect of depression onset on adherence to medication among hypertensive patients: a longitudinal modelling study. *J Hypertens.* 2013; 31: 1477-1484.
- 37 Abushouk AI, Sane Taheri M, Pooransari P, et al. Pregnancy screening before diagnostic radiography in emergency department: an educational review. *Emerg.* 2017; 5(1): e60, indexed in Pubmed: 28 894 775.
- 38 RSNA Statement on Safety of the Developing Fetus in Medical Imaging During Pregnancy. Reviewed: 04.03.2018. www.rsna.org/uploadedFiles/RSNA/

- 39 Bocking AD. Assessment of fetal heart rate and fetal movements in detecting oxygen deprivation in-utero. *Eur J Obstet Gynecol Reprod Biol.* 2003; 110 Suppl 1: S108-S112.
- 40 Practice bulletin no. 145: antepartum fetal surveillance. *Obstet Gynecol.* 2014; 124: 182-192.
- 41 Bartsch E, Medcalf KE, Park AL, et al. High Risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. *BMJ.* 2016; 353: i1753.
- 42 Baschat AA. Planning management and delivery of the growthrestricted fetus. *Best Pract Res Clin Obstet Gynaecol.* 2018; 49: 53-65.
- 43 Manning FA, Snijders R, Harman CR, et al. Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH. *Am J Obstet Gynecol.* 1993; 169: 755-763.
- 44 Turan S, Turan OM, Berg C, et al. Computerized fetal heart rate analysis, Doppler ultrasound and biophysical profile score in the prediction of acid-base status of growth-restricted fetuses. *Ultrasound Obstet Gynecol.* 2007; 30: 750-756.
- 45 Thompson RS, Trudinger BJ. Doppler waveform pulsatility index and resistance, pressure and flow in the umbilical placental circulation: an investigation using a mathematical model. *Ultrasound Med Biol.* 1990; 16: 449-458.
- 46 Hecher K, Bilardo CM, Stigter RH, et al. Monitoring of fetuses with intra-uterine growth restriction: a longitudinal study. *Ultrasound Obstet Gynecol.* 2001; 18: 564-570.
- 47 Weiner CP. The relationship between the umbilical artery systolic/ diastolic ratio and umbilical blood gas measurements in specimens obtained by cordocentesis. *Am J Obstet Gynecol.* 1990; 162: 1198-1202.
- 48 Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2009; 150: 626-631.
- 49 Ruager-Martin R, Hyde MJ, Modi N. Maternal obesity and infant outcomes. *Early Hum Dev.* 2010; 86: 715-722.
- 50 Zetterström K, Lindeberg SN, Haglund B, et al. Maternal complications in women with chronic hypertension: a populationbased cohort study. *Acta Obstet Gynecol Scand.* 2005; 84: 419-424.
- 51 Ananth CV, Savitz DA, Bowes WA, et al. Influence of hypertensive disorders and cigarette smoking on placental abruption and uterine bleeding during pregnancy. *Br J Obstet Gynaecol.* 1997; 104: 572-578.
- 52 Sibai BM, Lindheimer M, Hauth J, et al. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. *N Engl J Med.* 1998; 339: 667-671.
- 53 Cruz MO, Gao W, Hibbard JU. Obstetrical and perinatal outcomes among women with gestational hypertension, mild preeclampsia, and mild chronic hypertension. *Am J Obstet Gynecol.* 2011; 205: 260.e1-260.e9.
- 54 Hanson M, Bardsley A, De-Regil L, et al. The International Federation of Gynecology and Obstetrics (FIGO) recommendations on adolescent, preconception, and maternal nutrition: "Think Nutrition First". *Int J Gynecol Obstet.* 2015; 131: S213.
- 55 Sochaczewska D, Czeszyńska Maria B, Konefal H, et al. Assessment of relationship between cord blood cotinine levels and some factors of perinatal hypoxia. *Ginekol Pol.* 2009; 80: 920-926.
- 56 Polańska K, Hanke W. Influence of smoking during pregnancy on children's health - overview of epidemiologic studies. *Przegl Epidemiol.* 2005; 59: 117-123.
- 57 Kocińska-Najman B, Pietrzek B, Mazanowska N, et al. Fetal alcohol spectrum disorder. Breastfeeding and alcohol. *Ginekologia i Perinatologia Praktyczna.* 2017; 2: 93-109.
- 58 Antoniou T, Camacho X, Yao Z, et al. Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. *CMAJ.* 2013; 185: 1035-1041.
- 59 Niemiec T, Dębski R, Kotarski J, et al. The statement of Polish Gynaecologic Society experts concerning drinking water consumption in women in reproductive age, pregnancy and breast feeding. *Ginekol Pol.* 2009; 80: 538-47.
- 60 EFSA NDA Panel. EFSA Panel on Dietetic Products NaA. Scientific opinion on the safety of caffeine. *EFSA Journal.* 2015; 13: 4102.
- 61 Koletzko B, Cremer M, Flothkötter M, et al. Diet and lifestyle before and during pregnancy. Practical recommendations of the German-wide healthy start: young family network. *Geburtshilfe Frauenheilkd.* 2018; 78: 1262-1282.
- 62 Aune D, Schlesinger S, Henriksen T, et al. Physical activity and the risk of preterm birth: a systematic review and meta-analysis of epidemiological studies. *BJOG.* 2017; 124: 1816-1826.
- 63 Magro-Malosso ER, Saccone G, Di Tommaso M, et al. Exercise during pregnancy and risk of gestational hypertensive disorders: a systematic review and meta-analysis. *Acta Obstet Gynecol Scand.* 2017; 96: 921-931.
- 64 Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. *Cochrane Database Syst Rev.* 2001; 10: CD002252.
- 65 Magee LA, von Dadelzen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. *N Engl J Med.* 2015; 372: 407-417.
- 66 Webster LM, Conti-Ramsden F, Seed PT, et al. Impact of antihypertensive treatment on maternal and perinatal outcomes in pregnancy complicated by chronic hypertension. A systematic review and meta-analysis. *J Am Heart Assoc.* 2017; 6: pii: e005526.
- 67 Magee LA, von Dadelzen P, Singer J, et al. The CHIPS Randomized Controlled Trial (Control of hypertension in pregnancy study): ss severe hypertension just an elevated blood pressure? *Hypertension.* 2016; 68: 1153-1159.
- 68 Pels A, Mol BWJ, Singer J, et al. Influence of gestational age at initiation of antihypertensive therapy. *Hypertension.* 2018; 71:1170-1177.
- 69 Nzelu D, Dumitrascu-Biris D, Nicolaides KH, et al. Chronic hypertension: first-trimester blood pressure control and likelihood of severe hypertension, preeclampsia, and small for gestational age. *Am J Obstet Gynecol.* 2018; 218: 337.e1-337.e7.
- 70 Hoeltzenbein M, Beck E, Fietz AK, et al. Pregnancy outcome after first trimester use of methyldopa. A prospective cohort study. *Hypertension.* 2017; 70: 201-208.
- 71 Cockburn J, Moar VA, Ounsted M, et al. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. *Lancet.* 1982; 1: 647-649.
- 72 Duan L, Ng A, Chen W, et al. β -blocker exposure in pregnancy and risk of fetal cardiac anomalies. *JAMA Intern Med.* 2017; 177: 885-887.
- 73 Clark SM, Dunn HE, Hankins GDV. A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy. *Semin Perinatol.* 2015; 39: 548-555.
- 74 Yakoob MY, Bateman BT, Ho E, et al. The risk of congenital malformations associated with exposure to β -blockers early in pregnancy: a meta-analysis. *Hypertension.* 2013; 62: 375-381.
- 75 Pieper P. Use of medication for cardiovascular disease during pregnancy. *Nature Reviews Cardiology.* 2015; 12: 718-729.
- 76 Nakhai-Pour HR, Rey E, Bérard A. Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. *Birth Defects Res B Dev Reprod Toxicol.* 2010; 89: 147-154.
- 77 Meidahl Petersen K, Jimenez-Solem E, Andersen JT, et al. β -Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. *BMJ Open.* 2012; 2: pii: e001185.
- 78 Bortolus R, Ricci E, Chatenoud L, et al. Nifedipine administered in pregnancy: effect on the development of children at 18 months. *BJOG.* 2000; 107: 792-794.
- 79 Giannubilo SR, Bezzecheri V, Cecchi S, et al. Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. *Arch Gynecol Obstet.* 2012; 286: 637-642.
- 80 Gazzolo D, Visser GH, Russo A, et al. Pregnancy-induced hypertension, antihypertensive drugs and the development of fetal behavioural states. *Early Hum Dev.* 1998; 50: 149-157.
- 81 Jannet D, Carbone B, Sebban E, et al. Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: a randomized comparative trial. *Obstet Gynecol.* 1994; 84: 354-359.
- 82 Ahn HK, NavaOcampo AA, Han JY, et al. Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding. *Hypertens Pregnancy.* 2007; 26: 179-187.
- 83 Lawrence MR, Broughton Pipkin F. Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy. *Br J Clin Pharmacol.* 1987; 23: 683-692.
- 84 Allen J, Maigaard S, Forman A, et al. Acute effects of nitrendipine in pregnancy-induced hypertension. *Br J Obstet Gynaecol.* 1987; 94: 222-226.
- 85 Wide-Svensson DH, Ingemarsson I, Lunell NO, et al. Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study. *Am J Obstet Gynecol.* 1995; 173(3 Pt 1): 872-878.
- 86 Weber-Schoendorfer C, Hannemann D, Meister R, et al. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. *Reprod Toxicol.* 2008; 26: 24-30.
- 87 Sørensen HT, Czeizel AE, Rockenbauer M, et al. The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers. *Acta Obstet Gynecol Scand.* 2001; 80: 397-401.
- 88 Kurtzman JL, Thorp JM, Spielman FJ, et al. Do nifedipine and verapamil potentiate the cardiac toxicity of magnesium sulfate? *Am J Perinatol.* 1993; 10: 450-452.
- 89 Belfort MA, Anthony J, Buccimazza A, et al. Hemodynamic changes associated with intravenous infusion of the calcium antagonist verapamil in the treatment of severe gestational proteinuric hypertension. *Obstet Gynecol.* 1990; 75: 970-974.
- 90 Anugu VR, Nalluri N, Asti D, et al. New-onset lone atrial fibrillation in pregnancy. *Ther Adv Cardiovasc Dis.* 2016; 10: 274-276.
- 91 Ruys TPE, Maggioni A, Johnson MR, et al. Cardiac medication during pregnancy, data from the ROPAC. *Int J Cardiol.* 2014; 177: 124-128.
- 92 Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. *Hypertension.* 2012; 60: 444-450.
- 93 Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. *N Engl J Med.* 2006; 354: 2443-2451.

- 94 Magee LA, von Dadelszen P, Singer J, et al. Control of hypertension in pregnancy study randomised controlled trial—are the results dependent on the choice of labetalol or methyldopa? *BJOG*. 2016; 123: 1135-1141.
- 95 Moroz LA, Simpson LL, Rochelson B. Management of severe hypertension in pregnancy. *Semin Perinatol*. 2016; 40: 112-118.
- 96 Ryan R, McCarthy F. Hypertension in pregnancy. *Obstetrics, Gynecology & Reproductive Medicine*. 2018; 28: 141-147.
- 97 Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of preeclampsia. *JAMA*. 2002; 287: 3183-3186.
- 98 Matijević R, Johnston T. In vivo assessment of failed trophoblastic invasion of the spiral arteries in pre-eclampsia. *Br J Obstet Gynaecol*. 1999; 106: 78-82.
- 99 Meekins JW, Pijnenborg R, Hanssens M, et al. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. *Br J Obstet Gynaecol*. 1994; 101: 669-674.
- 100 Brownfoot F, Kaitu'u-Lino T, Beard S, et al. sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies? *Pregnancy Hypertens*. 2017; 10: 18-21.
- 101 Yliniemi A, Makikallio K, Korpimäki T, et al. Combination of PAPP-A, fhCGβ, AFP, PlGF, sTNFR1, and maternal characteristics in prediction of early-onset preeclampsia. *Clin Med Insights Reprod Health*. 2015; 9: 13-20.
- 102 Roberts L, Chaemsaitong P, Sahota DS, et al. Protocol for measurement of mean arterial pressure at 10-40 weeks' gestation. *Pregnancy Hypertens*. 2017; 10: 155-160.
- 103 Tan MY, Syngelaki A, Poon LC, et al. ASPRE trial: incidence of preterm pre-eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm. *Ultrasound Obstet Gynecol*. 2018; 51: 738-742.
- 104 Velauthar L, Plana MN, Kalidindi M, et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55,974 women. *Ultrasound Obstet Gynecol*. 2014; 43: 500-507.
- 105 Kleinrouweler CE, Bossuyt PMM, Thilaganathan B, et al. Value of adding second-trimester uterine artery Doppler to patient characteristics in identification of nulliparous women at increased risk for pre-eclampsia: an individual patient data meta-analysis. *Ultrasound Obstet Gynecol*. 2013; 42: 257-267.
- 106 Cnossen JS, Morris RK, ter Riet G, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. *CMAJ*. 2008; 178: 701-711.
- 107 Papageorgiou A, Yu C, Erasmus I, et al. Assessment of risk for the development of pre-eclampsia by maternal characteristics and uterine artery Doppler. *BJOG*. 2005; 112: 703-709.
- 108 Martin AM, Bindra R, Curcio P, et al. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation. *Ultrasound Obstet Gynecol*. 2001; 18: 583-586.
- 109 Yu CKH, Smith GCS, Papageorgiou AT, et al. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. *Am J Obstet Gynecol*. 2005; 193: 429-436.
- 110 Poon LCY, Kametas NA, Maiz N, et al. First-trimester prediction of hypertensive disorders in pregnancy. *Hypertension*. 2009; 53: 812-818.
- 111 Poon LC, Nicolaides KH. Early prediction of preeclampsia. *Obstet Gynecol Int*. 2014; 2014: 297-397.
- 112 Gallo DM, Wright D, Casanova C, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation. *Am J Obstet Gynecol*. 2016; 214: 619.e1-619.e17.
- 113 Agrawal S, Cerdeira AS, Redman C, et al. Meta-analysis and systematic review to assess the role of soluble FMS-like tyrosine kinase-1 and placenta growth factor ratio in prediction of preeclampsia: the SaPPPhrE Study. *Hypertension*. 2018; 71: 306-316.
- 114 Zeisler H, Llurba E, Chantraine F, et al. Soluble FMS-like tyrosine kinase-1-to-placental growth factor ratio and time to delivery in women with suspected preeclampsia. *Obstet Gynecol*. 2016; 128: 261-269.
- 115 Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt1:PlGF ratio in women with suspected preeclampsia. *N Engl J Med*. 2016; 374: 13-22.
- 116 Dragan I, Georgiou T, Prodan N, et al. Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation. *Ultrasound Obstet Gynecol*. 2017; 49: 73-77.
- 117 Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. *Am J Obstet Gynecol*. 2018; 218: 287-293.e1.
- 118 Bujold E, Roberge S, Nicolaides KH. Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation. *Prenat Diagn*. 2014; 34: 642-648.
- 119 Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. *N Engl J Med*. 2017; 377: 613-622.
- 120 Hermida RC, Ayala DE, Mojón A, et al. Ambulatory blood pressure control with bedtime aspirin administration in subjects with prehypertension. *Am J Hypertens*. 2009; 22: 896-903.
- 121 Steegers EAP, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. *Lancet*. 2010; 376: 631-644.
- 122 Zhao M, Yin Y, Wei J, et al. Trophoblastic debris extruded from hydatidiform molar placenta activates endothelial cells: Possible relevance to the pathogenesis of preeclampsia. *Placenta*. 2016; 45: 42-49.
- 123 Huppertz B. Trophoblast differentiation, fetal growth restriction and preeclampsia. *Pregnancy Hypertens*. 2011; 1: 79-86.
- 124 Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. *Cochrane Database Syst Rev*. 2007; 1: CD002252.
- 125 Duley L, Henderson-Smith DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. *Cochrane Database Syst Rev*. 2006; 3: CD00144.
- 126 Centers for Disease Control and Prevention (CDC). Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy—United States, Canada, and Israel, 1987-1995. *MMWR Morb Mortal Wkly Rep*. 1997; 46: 240-242.
- 127 Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. *N Engl J Med*. 2006; 354: 2443-2451.
- 128 Easterling TR, Carr DB, Brateng D, et al. Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. *Obstet Gynecol*. 2001; 98: 427-433.
- 129 Cruz MO, Gao W, Hibbard JU. What is the optimal time for delivery in women with gestational hypertension? *Am J Obstet Gynecol*. 2012; 207: e1-e6.
- 130 Duley L, Gulmezoglu AM, Henderson-Smith DJ, et al. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. *Cochrane Database Syst Rev*. 2010; 11: CD000025.
- 131 Marret S, Marpeau L, Zupan-Simunek V, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. *BJOG*. 2007; 114: 310-318.
- 132 Roberts D, Brown J, Medley N, et al. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev*. 2006; 3: CD004454.
- 133 Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicenter, open-label randomised controlled trial. *Lancet*. 2009; 374: 979-988.
- 134 Plouin PF, Baguet JP, Thony F, et al. High prevalence of multiple arterial bed lesions in patients with fibromuscular dysplasia: The ARCADIA Registry (Assessment of Renal and Cervical Artery Dysplasia). *Hypertension*. 2017; 70: 652-658.
- 135 Dobrowolski P, Januszewicz M, Klisiewicz A, et al. Echocardiographic assessment of left ventricular morphology and function in patients with fibromuscular dysplasia: the ARCADIA-POL study. *J Hypertens*. 2018; 36: 1318-1325.
- 136 Gornik HL, Persu A, Adlam D, et al. First international consensus on the diagnosis and management of fibromuscular dysplasia. *J Hypertens*. 2019; 37: 229-252.
- 137 Khan F, Ghani AR, Mackenzie L, et al. A rare presentation of fibromuscular dysplasia: postpartum vascular catastrophe and brief literature review. *J Investig Med High Impact Case Rep*. 2017; 5: 23247096177191917.
- 138 Shoja T, Basman C, Jain S, et al. Postpartum sudden cardiac death after spontaneous coronary artery dissection in a patient with fibromuscular dysplasia. *Cardiol Res*. 2017; 8: 327-330.
- 139 Kadian-Dodov D, Gornik HL, Gu X, et al. Dissection and aneurysm in patients with fibromuscular dysplasia: findings from the U.S. Registry for FMD. *J Am Coll Cardiol*. 2016; 68: 176-185.
- 140 Touzé E, Southerland AM, Boulanger M, et al. Fibromuscular dysplasia and its neurologic manifestations: a systematic review. *JAMA Neurol*. 2018 [Epub ahead of print].
- 141 Talarowska P, Dobrowolski P, Klisiewicz A, et al. High incidence and clinical characteristics of fibromuscular dysplasia in patients with spontaneous cervical artery dissection: The ARCADIA-POL study. *Vasc Med*. 2019; 24: 112-119.
- 142 Vance CJ, Taylor RN, Craven TE, et al. Increased prevalence of preeclampsia among women undergoing procedural intervention for renal artery fibromuscular dysplasia. *Ann Vasc Surg*. 2015; 29: 1105-1110.
- 143 Berra E, Dominiczak AF, Touyz RM, et al. Management of a pregnant woman with fibromuscular dysplasia. *Hypertension*. 2018; 71: 540-547.
- 144 Kaszuba AM, Prejbisz A, Kądziała J, et al. Forty-two-year-old female patient with resistant hypertension, bilateral renal fibromuscular dysplasia and intracranial aneurysm. *Postępy Kardiologii Interwencyjnej*. 2016; 12: 386-388.
- 145 Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2016; 101(5): 1889-1916.
- 146 Young W, Calhoun D, Lenders J, et al. Screening for endocrine hypertension: an endocrine society scientific statement. *Endocrine Reviews*. 2017; 38: 103-122.
- 147 Riestler A, Reincke M. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy. *Eur J Endocrinol*. 2015; 172(1): R23- R30, doi: 10.1530/EJE-14-0444, indexed in Pubmed: 25163723.
- 148 Morton A. Primary aldosteronism and pregnancy. *Pregnancy Hypertens*. 2015; 5: 259-262.

- 149 Landau E, Amar L. Primary aldosteronism and pregnancy. *Ann Endocrinol (Paris)*. 2016; 77: 148-160.
- 150 Kądziała J, Prejbisz A, Michałowska I, et al. A single-center experience of the implementation of adrenal vein sampling procedure: the impact on the diagnostic work-up in primary aldosteronism. *Kardiologia Pol.* 2017; 75: 28-34.
- 151 Lenders J, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2014; 99: 1915-1942.
- 152 Lenders JW. Pheochromocytoma and pregnancy: a deceptive connection. *Eur J Endocrinol.* 2012; 166: 143-150.
- 153 Weerd Kv, Noord Cv, Loeve M, et al. Endocrinology in pregnancy: pheochromocytoma in pregnancy: case series and review of literature. *Eur J Endocrinol.* 2017; 177: R49-R58.
- 154 Wing L, Conaglen J, Meyer-Rochow G, et al. Paraganglioma in pregnancy: a case series and review of the literature. *J Clin Endocrinol Metab.* 2015; 100: 3202-3209.
- 155 Jozwick-Plebanek K, Peczkowska M, Klisiewicz A, et al. Pheochromocytoma presenting as takotsubo-like cardiomyopathy following delivery. *Endocr Pract.* 2014; 20: e233-e236.
- 156 Prejbisz A, Lenders J, Eisenhofer G, et al. Cardiovascular manifestations of pheochromocytoma. *J Hypertens.* 2011; 29: 2049-2060.
- 157 Eisenhofer G, Prejbisz A, Peitzsch M, et al. Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated o-methylated catecholamine metabolites. *Clin Chem.* 2018; 64: 1646-1656.
- 158 Canniffe C, Ou P, Walsh K, et al. Hypertension after repair of aortic coarctation. A systematic review. *Int J Cardiol.* 2013; 167: 2456-2461.
- 159 Vriend J, Drenthen W, Pieper P, et al. Outcome of pregnancy in patients after repair of aortic coarctation. *Eur Heart J.* 2005; 26: 2173-2178.
- 160 Beauchesne L, Connolly H, Ammash N, et al. Coarctation of the aorta: outcome of pregnancy. *J Am Coll Cardiol.* 2001; 38: 1728-1733.
- 161 McKellar S, MacDonald R, Michelen H, et al. Frequency of cardiovascular events in women with a congenitally bicuspid aortic valve in a single community and effect of pregnancy on events. *Am J Cardiol.* 2011; 107: 96-99.
- 162 Wilson D, Barnes M, Ellett L, et al. Decreased sleep efficiency, increased wake after sleep onset and increased cortical arousals in late pregnancy. *Aust N Z J Obstet Gynaecol.* 2010; 51: 38-46.
- 163 Peppard PE, Young T, Barnett JH, et al. Increased prevalence of sleep-disordered breathing in adults. *Am J Epidemiol.* 2013; 177: 1006-1014.
- 164 Pien G, Pack A, Jackson N, et al. Risk factors for sleep-disordered breathing in pregnancy. *Thorax.* 2013; 69(4): 371-377, doi: 10.1136/thoraxjnl-2012-202718.
- 165 Macgillivray I, Campbell D. The Relevance of hypertension and oedema in pregnancy. *Clinical and Experimental Hypertension.* 2009; 2: 897-914.
- 166 Pilkington S, Carli F, Dakin MJ, et al. Increase in Mallampati score during pregnancy. *Br J Anaesth.* 1995; 74: 638-642.
- 167 Izci B. Sleep-disordered breathing and upper airway size in pregnancy and post-partum. *Eur Respir J.* 2006; 27: 321-327.
- 168 Bourjeily G, Danilack V, Bubltz M, et al. 0474 A national cohort study of obstructive sleep apnea in pregnancy and adverse neonatal outcomes. *Sleep.* 2017; 40 (Suppl. 1): A177.
- 169 Louis J, Auckley D, Miladinovic B, et al. Perinatal outcomes associated with obstructive sleep apnea in obese pregnant women. *Obstet Gynecol.* 2012; 120:1085-92.
- 170 Higgins N, Leong E, Park CS, et al. The Berlin Questionnaire for assessment of sleep disordered breathing risk in parturients and non-pregnant women. *Int J Obstet Anesth.* 2011; 20: 22-25.
- 171 Pengo M, Rossi G, Steier J. Obstructive sleep apnea, gestational hypertension and preeclampsia. *Curr Opin Pulm Med.* 2014; 20: 588-594.
- 172 Piccoli G, Cabiddu G, Attini R, et al. Hypertension in CKD pregnancy: a question of cause and effect (cause or effect? this is the question). *Current Hypertension Reports.* 2016; 18: 35.
- 173 Hall M. Pregnancy in women with CKD: a success story. *Am J Kidney Dis.* 2016; 68(4): 633-639.
- 174 Gonzalez Suarez ML, Kattah A, Grande JP, et al. Renal disorders in pregnancy: core curriculum 2019. *Am J Kidney Dis.* 2019; 73: 119-130.
- 175 Krane N, Hamrahian M. Pregnancy: kidney diseases and hypertension. *Am J Kidney Dis.* 2007; 49: 336-345.
- 176 Zhang JJ, Ma XX, Hao Li, et al. A systematic review and meta-analysis of outcomes of pregnancy in ckd and ckd outcomes in pregnancy. *Clinical Journal of the American Society of Nephrology.* 2015; 10: 1964-1978.
- 177 Bateman B, Bansil P, Hernandez-Diaz S, et al. Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions. *Am J Obstet Gynecol.* 2012; 206: 134.e1-134.e8.
- 178 Jesudason S, Mohammadi F, Fitzpatrick A. Managing pregnancy in chronic kidney disease: improving outcomes for mother and baby. *Int J Womens Health.* 2016; 8: 273-285.
- 179 Piccoli G, Cabiddu G, Attini R, et al. Risk of adverse pregnancy outcomes in women with CKD. *J Am Soc Nephrol.* 2015; 26: 2011-2022.
- 180 Alkhunaizi A, Melamed N, Hladunewich M. Pregnancy in advanced chronic kidney disease and end-stage renal disease. *Current Opinion in Nephrology and Hypertension.* 2015; 24: 252-259.
- 181 Wiles K, Nelson-Piercy C, Bramham K. Reproductive health and pregnancy in women with chronic kidney disease. *Nature Reviews Nephrology.* 2018; 14: 165-184.
- 182 Cabiddu G, Castellino S, Gernone G, et al. Best practices on pregnancy on dialysis: the Italian Study Group on Kidney and Pregnancy. *Journal of Nephrology.* 2015; 28: 279-288.
- 183 Koulouridis I, Alfayez M, Trikalinos T, et al. Dose of erythropoiesisstimulating agents and adverse outcomes in CKD: a metaregression analysis. *Am J Kidney Dis.* 2013; 61: 44-56.
- 184 Hladunewich M, Schatell D. Intensive dialysis and pregnancy. *Hemodialysis International.* 2016; 20: 339-348.
- 185 Katritsis DG, Boriani G, Cosio FG, et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE). *EP Europace.* 2017; 19: 465-511.
- 186 Vaidya VR, Arora S, Patel N, et al. Burden of arrhythmia in pregnancy. *Circulation.* 2017; 135: 619-621.
- 187 Drenthen W, Pieper PG, Roos-Hessink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. *J Am Coll Cardiol.* 2007; 49: 2303-2311.
- 188 Upshaw CB. A study of maternal electrocardiograms recorded during labor and delivery. *Am J Obstet Gynecol.* 1970; 107: 17-27.
- 189 Shotan A, Ostrzega E, Mehra A, et al. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. *Am J Cardiol.* 1997; 79: 1061-1064.
- 190 Chang SH, Kuo CF, Chou JJ, et al. Outcomes associated with paroxysmal supraventricular tachycardia during pregnancy. *Circulation.* 2017; 135: 616-618.
- 191 Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Pediatric and Congenital Cardiology (AEPC). *Europace.* 2015; 17: 1601-1687.
- 192 Szumowski L, Szufładowicz E, Orczykowski M, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. *J Cardiovasc Electrophysiol.* 2010; 21: 877-882.
- 193 Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur J Cardiothorac Surg.* 2016; 50: e1-e88.
- 194 Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. *LQTS Investigators. Circulation.* 1998; 97: 451-456.
- 195 Elkayam U, Jainapurkar S, Barakkat MN, et al. Pregnancy-associated acute myocardial infarction: a review of contemporary experience in 150 cases between 2006 and 2011. *Circulation.* 2014; 129: 1695-1702.
- 196 Faden MS, Bottega N, Benjamin A, et al. A nationwide evaluation of spontaneous coronary artery dissection in pregnancy and the puerperium. *Heart.* 2016; 102: 1974-1979.
- 197 Adlam D, Alfonso F, Maas A, et al. European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. *Eur Heart J.* 2018; 39: 3353-3368.
- 198 Hayes SN, Kim ESH, Saw J, et al. Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. *Circulation.* 2018; 137(19): e523-e557.
- 199 Appleby CE, Barolet A, Ing D, et al. Contemporary management of pregnancy-related coronary artery dissection. A single-center experience and literature review. *Exp Clin Cardiol.* 2009; 14: e8-ee16.
- 200 Havakuk O, Goland S, Mehra A, et al. Pregnancy and the risk of spontaneous coronary artery dissection: an analysis of 120 contemporary cases. *Circ Cardiovasc Interv.* 2017; 10: pii: e004941.
- 201 Tweet MS, Hayes SN, Codi E, et al. Spontaneous coronary artery dissection associated with pregnancy. *J Am Coll Cardiol.* 2017; 70: 426-435.
- 202 Higgins GL, Borofsky JS, Irish CB, et al. Spontaneous peripartum coronary artery dissection presentation and outcome. *J Am Board Fam Med.* 2013; 26: 82-89.
- 203 Tweet MS, Eleid MF, Best PJM, et al. Spontaneous coronary artery dissection: revascularization versus conservative therapy. *Circ Cardiovasc Interv.* 2014; 7: 777-786.
- 204 Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. *Lancet.* 2006; 368: 687-693.
- 205 Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. *Cell.* 2007; 128: 589-600.
- 206 Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. *Eur J Heart Fail.* 2016; 18: 1096-1105.

- 207 Hilfiger-Kleiner D, Haghighi A, Nonhoff J, et al. Peripartum cardiomyopathy: current management and future perspectives. *Eur Heart J*. 2015; 36: 1090-1097.
- 208 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Kardiol Pol*. 2016; 74: 1037-147.
- 209 Koenig T, Hilfiger-Kleiner D, Bauersachs J. Peripartum cardiomyopathy. *Herz*. 2018; 43: 431-437.
- 210 Bramham K, Nelson-Piercy C, Brown MJ, et al. Postpartum management of hypertension. *BMJ*. 2013; 346: f894.
- 211 Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. *Hypertension*. 2018; 72: 24-43.
- 212 Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: summary of NICE guidance. *BMJ*. 2011; 343: d4891.
- 213 Manninen AK, Juhakoski A. Nifedipine concentrations in maternal and umbilical serum, amniotic fluid, breast milk and urine of mothers and offspring. *Int J Clin Pharmacol Res*. 1991; 11: 231-236.
- 214 Sachs HC. Committee on Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. *Pediatrics*. 2013; 132: e796-e809.
- 215 McManus RJ, Caulfield M, Williams B. NICE hypertension guideline 2011: evidence based evolution. *BMJ*. 2012; 344: e181.
- 216 Aye CYL, Elmahi E, Boardman H, et al. Do young women need treatment for hypertension after pregnancy complications? *J Am Heart Assoc*. 2018; 7: pii: e009159.
- 217 Romundstad PR, Magnussen EB, Smith GD, et al. Hypertension in pregnancy and later cardiovascular risk: common antecedents? *Circulation*. 2010; 122: 579-584.
- 218 Stuart JJ, Tanz LJ, Missmer SA, et al. Hypertensive disorders of pregnancy and maternal cardiovascular disease risk factor development. An observational cohort study. *Ann Intern Med*. 2018; 169: 224-232.
- 219 Ditisheim A, Wuerzner G, Ponte B, et al. Prevalence of hypertensive phenotypes after preeclampsia. A prospective cohort study. *Hypertension*. 2018; 71: 103-109.
- 220 Podymow T, August P. Postpartum course of gestational hypertension and preeclampsia. *Hypertens Pregnancy*. 2010; 29: 294-300.
- 221 Haug EB, Horn J, Markovitz AR, et al. Life course trajectories of cardiovascular risk factors in women with and without hypertensive disorders in first pregnancy. The HUNT study in Norway. *J Am Heart Assoc*. 2018; 7: e009250.
- 222 Groenhouf TK, Zoet GA, Franx A, et al. Trajectory of cardiovascular risk factors after hypertensive disorders of pregnancy. *Hypertension*. 2019; 73: 171-178.
- 223 Zoet GA, Benschop L, Boersma E, et al. Prevalence of subclinical coronary artery disease assessed by coronary computed tomography angiography in 45 to 55-year-old women with a history of preeclampsia. *Circulation*. 2018; 137: 877-879.
- 224 Zoet GA, Linstra KM, Bernsen ML, et al. Stroke after pregnancy disorders. *Eur J Obstet Gynecol Reprod Biol*. 2017; 215: 264-266.
- 225 Skjaerven R, Wilcox AJ, Klungsøyr K, et al. Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study. *BMJ*. 2012; 345: e7677.
- 226 Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. *Hypertension*. 2010; 56: 166-171.
- 227 Bellamy L, Casas JP, Hingorani AD, et al. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ*. 2007; 335: 974.
- 228 Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health: A systematic review and meta-analysis. *Circ Cardiovasc Qual Outcomes*. 2017; 10: pii: e003497.
- 229 Cortés YI, Catov JM, Brooks M, et al. History of adverse pregnancy outcomes, blood pressure, and subclinical vascular measures in late midlife: SWAN (Study of Women's Health Across the Nation). *J Am Heart Assoc*. 2017; 7: pii: e007138.
- 230 Ahmed R, Dunford J, Mehran R, et al. Pre-eclampsia and future cardiovascular risk among women: a review. *J Am Coll Cardiol*. 2014; 63: 1815-1822.
- 231 Spaan J, Peeters L, Spaanderman M, et al. Cardiovascular risk management after a hypertensive disorder of pregnancy. *Hypertension*. 2012; 60: 1368-1373.
- 232 Wolfenstetter A, Simonetti GD, Pöschl J, et al. Altered cardiovascular rhythmicity in children born small for gestational age. *Hypertension*. 2012; 60: 865-870.
- 233 Simonetti GD, Raio L, Surbek D, et al. Salt sensitivity of children with low birth weight. *Hypertension*. 2008; 52: 625-630.
- 234 Shah AB, Hashmi SS, Sahulee R, et al. Characteristics of systemic hypertension in preterm children. *J Clin Hypertens*. 2015; 17: 364-370.
- 235 de Jong F, Monuteaux MC, van Elburg RM, et al. Systematic review and meta-analysis of preterm birth and later systolic blood pressure. *Hypertension*. 2012; 59: 226-234.
- 236 Luyckx VA, Perico N, Somaschini M, et al. A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. *Lancet*. 2017; 390: 424-428.
- 237 Litwin M. Standardowy powypisowy, wczesnej diagnostyki nadciśnienia tętniczego u dzieci urodzonych przedwcześnie i obserwowanych do końca 3 r.ż. Standardy opieki ambulatoryjnej nad dzieckiem urodzonym przedwcześnie Zalecenia Polskiego Towarzystwa Neonatologicznego i Polskiego Towarzystwa Pediatrycznego [Guidelines for outpatient, early diagnosis of hypertension in pre-term born children up to 3 years of age. Standards of care for pre-term born children. Guidelines of Polish Society of Neonatology and Polish Pediatric Society]. Media Press, Warszawa 2018.
- 238 Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. *J Hypertens*. 2016; 34: 1887-1920.
- 239 Litwin M, Niemirska A, Obrycki L, et al. Guidelines of the Pediatric Section of the Polish Society of Hypertension on diagnosis and treatment of arterial hypertension in children and adolescents. *Arter Hypertens*. 2018; 22: 45-73.
- 240 Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management and outcome. *Pediatr Nephrol*. 2012; 27: 17-32.
- 241 Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics*. 2017; 140: pii: e20181739.
- 242 Kułaga Z, Litwin M, Grajda A, et al. OLAF Study Group. Oscillometric blood pressure percentiles for Polish normalweight school-aged children and adolescents. *J Hypertens*. 2012; 30: 1942-1954.